Advanced Search
MyIDEAS: Login

Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data

Contents:

Author Info

  • Lichtenberg Frank R.

    ()
    (Columbia University)

Abstract

This study examines the impact of pharmaceutical innovation and other factors on the survival of U.S. cancer patients during the period 1992-2003. In particular, it investigates whether cancer survival rates increased more for those cancer sites that had the largest increases in the proportion of chemotherapy treatments that were "new" treatments. We control for other types of medical innovation, i.e. other pharmaceutical innovation, and innovation in surgical procedures, diagnostic radiology procedures, and radiation oncology procedures.Data on observed survival rates, the number of people diagnosed, mean age at diagnosis, and stage distribution are obtained from the National Cancer Institute’s SEER public-use data. Estimates of rates of innovation in chemotherapy and other treatment and diagnostic procedures are constructed from the MEDSTAT MarketScan database and other data sources. Treatment innovation indicators based on MEDSTAT data are likely to be useful, albeit noisy, indicators of the treatment innovation experienced by patients in SEER registries. This sampling error is likely to bias the coefficients on the treatment innovation measures towards zero.We compute weighted least-squares estimates of 6 versions of a survival model, based on different survival intervals and functional forms. The chemotherapy vintage coefficient is positive and significant in every model. This indicates that the cancer sites whose chemotherapy vintage (measured by the share of post-1990 treatments) increased the most during the period 1992-2003 tended to have larger increases in observed survival rates, ceteris paribus.We estimate how much lower the survival rate from all cancer sites combined would have been during 1993-2001 in the absence of post-1992 chemotherapy innovation. The estimates indicate that chemotherapy innovation accounted for 74% of the increase in the 1-year observed survival rate for all cancer sites combined during the period 1992-2001. Chemotherapy innovation accounted for smaller fractions of the increases in the 2-year and 3-year observed survival rates for all cancer sites combined during the same period: 51% and 29%, respectively.The coefficients on measures of non-pharmaceutical medical innovation (in radiation oncology, diagnostic radiology, and surgery innovation) are generally not significant. However these measures may be less reliable than the drug innovation measure. They were based upon the year in which the AMA established a new procedure code, which may be a far less meaningful indicator of innovation than the year in which the FDA first approved a drug. This topic warrants further research.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://www.degruyter.com/view/j/fhep.2008.10.1/fhep.2008.10.1.1090/fhep.2008.10.1.1090.xml?format=INT
Download Restriction: For access to full text, subscription to the journal or payment for the individual article is required.

As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

Bibliographic Info

Article provided by De Gruyter in its journal Forum for Health Economics & Policy.

Volume (Year): 10 (2008)
Issue (Month): 1 (March)
Pages: 1-27

as in new window
Handle: RePEc:bpj:fhecpo:v:10:y:2008:i:1:n:1

Contact details of provider:
Web page: http://www.degruyter.com

Order Information:
Web: http://www.degruyter.com/view/j/fhep

Related research

Keywords:

References

No references listed on IDEAS
You can help add them by filling out this form.

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as in new window

Cited by:
  1. Vincenzo Atella & Francesco D'Amico, 2010. "Who is responsible for your health: You, your doctor or new technologies?," CEIS Research Paper 167, Tor Vergata University, CEIS, revised 28 May 2010.

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:bpj:fhecpo:v:10:y:2008:i:1:n:1. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Peter Golla).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.